Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Costa

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|April 10, 2008
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio studyGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Journal of the National Cancer Institute|April 10, 2008
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trialGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|December 16, 2014
Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophiliaLydia Luley, Anne Schumacher, Melissa J Mulla, et al.
Annals of Surgical Oncology|September 20, 2006
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trialSibylle Loibl, Gunter von Minckwitz, Günther Raab, et al.
BMC Cancer|July 15, 2015
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)Max Seidensticker, Benjamin Garlipp, Sophia Scholz, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|December 25, 2007
Supporting the hypothesis of pregnancy as a tumor: survivin is upregulated in normal pregnant mice and participates in human trophoblast proliferationStefan Fest, Nadja Brachwitz, Anne Schumacher, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2009
Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancyAnne Schumacher, Nadja Brachwitz, Sindy Sohr, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer Research and Treatment|June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsSibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|April 10, 2008
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio studyGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
Journal of the National Cancer Institute|April 10, 2008
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trialGunter von Minckwitz, Sherko Kümmel, Petra Vogel, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|December 16, 2014
Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophiliaLydia Luley, Anne Schumacher, Melissa J Mulla, et al.
Annals of Surgical Oncology|September 20, 2006
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trialSibylle Loibl, Gunter von Minckwitz, Günther Raab, et al.
BMC Cancer|July 15, 2015
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)Max Seidensticker, Benjamin Garlipp, Sophia Scholz, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|December 25, 2007
Supporting the hypothesis of pregnancy as a tumor: survivin is upregulated in normal pregnant mice and participates in human trophoblast proliferationStefan Fest, Nadja Brachwitz, Anne Schumacher, et al.
Clinical Breast Cancer|November 12, 2002
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisChristian Jackisch, Gunter von Minckwitz, Holger Eidtmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2009
Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancyAnne Schumacher, Nadja Brachwitz, Sindy Sohr, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Bianca Lederer, Jens-Uwe Blohmer, et al.
Breast Cancer Research and Treatment|June 26, 2015
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trialsSibylle Loibl, Christian Jackisch, Bianca Lederer, et al.
Pageof 10